Literature DB >> 31144477

Regional variations in longitudinal pulmonary function: A comparison of Hispanic and non-Hispanic subjects with cystic fibrosis in the United States.

Meghan E McGarry1, John M Neuhaus2, Dennis W Nielson1, Ngoc P Ly1.   

Abstract

BACKGROUND: Hispanic subjects with cystic fibrosis (CF) have increased morbidity and mortality than non-Hispanic white subjects. The ethnic disparity in mortality varies by region. Factors influencing pulmonary function vary by both ethnicity and region.
OBJECTIVE: To determine if the ethnic difference in pulmonary function varies by region.
METHODS: This retrospective cohort study compared differences in longitudinal pulmonary function (percent-predicted forced vital capacity [FVC], forced expiratory volume in 1 second [FEV1 ], forced expiratory flow at 25% to 75% [FEF25-75 ], FEV1 /FVC, and FEV1 decline) between Hispanic and non-Hispanic white subjects with CF by Census region of the United States (West, South, Midwest, and Northeast). Subjects were of ages 6 to 25 years and in the CF Foundation Patient Registry from 2008 to 2013. We used linear mixed effects models with subject-specific slopes and intercepts, adjusting for 14 demographic and clinical variables.
RESULTS: Of 14 932 subjects, 1433 (9.6%) were Hispanic and 13 499 (90.4%) were non-Hispanic white. Hispanic subjects' FEV1 was 9.0% (8.3%-9.8%) lower than non-Hispanic white subjects in the West, while Hispanic subjects' FEV1 was only 4.0% (3.0%-5.0%) lower in the Midwest, 4.4% (3.1%-5.7%) lower in the Northeast, and 4.4% (3.2%-5.5%) lower in the South. Similarly, FVC and FEF25-75 were lower among Hispanic subjects compared to non-Hispanic white subjects in all US regions, with the biggest differences in the West. Only in the West was FEV1 /FVC significantly lower in Hispanic subjects (-0.019; -0.022 to -0.015). FEV1 decline was not significantly different between ethnicities in any region.
CONCLUSIONS: In CF, Hispanic subjects have lower pulmonary function than non-Hispanic white subjects in all geographic regions with the largest difference in occurring in the West.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  cystic fibrosis; epidemiology; pulmonary function testing; social dimensions of pulmonary medicine

Year:  2019        PMID: 31144477      PMCID: PMC6702095          DOI: 10.1002/ppul.24377

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  32 in total

1.  Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: A longitudinal analysis.

Authors:  Meghan E McGarry; John M Neuhaus; Dennis W Nielson; Esteban Burchard; Ngoc P Ly
Journal:  Pediatr Pulmonol       Date:  2017-10-30

2.  "Where they (live, work and) spray": pesticide exposure, childhood asthma and environmental justice among Mexican-American farmworkers.

Authors:  Norah Anita Schwartz; Christine Alysse von Glascoe; Victor Torres; Lorena Ramos; Claudia Soria-Delgado
Journal:  Health Place       Date:  2015-02-06       Impact factor: 4.078

3.  Long-term outcomes of children with intermediate sweat chloride values in infancy.

Authors:  Tyler Groves; Paul Robinson; Veronica Wiley; Dominic A Fitzgerald
Journal:  J Pediatr       Date:  2015-03-23       Impact factor: 4.406

4.  Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

Authors:  D E Geller; H Kaplowitz; M J Light; A A Colin
Journal:  Chest       Date:  1999-09       Impact factor: 9.410

5.  CDC growth charts: United States.

Authors:  R J Kuczmarski; C L Ogden; L M Grummer-Strawn; K M Flegal; S S Guo; R Wei; Z Mei; L R Curtin; A F Roche; C L Johnson
Journal:  Adv Data       Date:  2000-06-08

6.  Disparities in access to lung transplantation for patients with cystic fibrosis by socioeconomic status.

Authors:  Bradley S Quon; Kevin Psoter; Nicole Mayer-Hamblett; Moira L Aitken; Christopher I Li; Christopher H Goss
Journal:  Am J Respir Crit Care Med       Date:  2012-09-13       Impact factor: 21.405

Review 7.  Socioeconomic status and health outcomes: cystic fibrosis as a model.

Authors:  Gabriela R Oates; Michael S Schechter
Journal:  Expert Rev Respir Med       Date:  2016-06-09       Impact factor: 3.772

8.  The language spoken at home and disparities in medical and dental health, access to care, and use of services in US children.

Authors:  Glenn Flores; Sandra C Tomany-Korman
Journal:  Pediatrics       Date:  2008-06       Impact factor: 7.124

9.  Decreased lung function in 7-year-old children with early-life organophosphate exposure.

Authors:  Rachel Raanan; John R Balmes; Kim G Harley; Robert B Gunier; Sheryl Magzamen; Asa Bradman; Brenda Eskenazi
Journal:  Thorax       Date:  2015-12-03       Impact factor: 9.139

10.  Disparities in Mortality of Hispanic Patients with Cystic Fibrosis in the United States. A National and Regional Cohort Study.

Authors:  Jason Rho; Chul Ahn; Ang Gao; Gregory S Sawicki; Ashley Keller; Raksha Jain
Journal:  Am J Respir Crit Care Med       Date:  2018-10-15       Impact factor: 21.405

View more
  8 in total

Review 1.  Socioeconomic determinants of respiratory health in patients with cystic fibrosis: implications for treatment strategies.

Authors:  Gabriela R Oates; Michael S Schechter
Journal:  Expert Rev Respir Med       Date:  2022-06-23       Impact factor: 4.300

2.  Evaluating Differences in the Disease Experiences of Minority Adults With Cystic Fibrosis.

Authors:  Kia Hutchins; Eileen Barr; Cecelia Bellcross; Nadia Ali; William R Hunt
Journal:  J Patient Exp       Date:  2022-07-14

Review 3.  The demographics of adverse outcomes in cystic fibrosis.

Authors:  Meghan E McGarry; Wadsworth A Williams; Susanna A McColley
Journal:  Pediatr Pulmonol       Date:  2019-11

4.  Early acquisition and conversion of Pseudomonas aeruginosa in Hispanic youth with cystic fibrosis in the United States.

Authors:  Meghan E McGarry; Chiung-Yu Huang; Dennis W Nielson; Ngoc P Ly
Journal:  J Cyst Fibros       Date:  2020-11-05       Impact factor: 5.482

5.  Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype.

Authors:  Meghan E McGarry; Susanna A McColley
Journal:  Pediatr Pulmonol       Date:  2021-02-01

Review 6.  Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis.

Authors:  Meghan E McGarry; Elizabeth R Gibb; Gabriela R Oates; Michael S Schechter
Journal:  Paediatr Respir Rev       Date:  2021-12-22       Impact factor: 5.526

7.  Telehealth use in cystic fibrosis during COVID-19: Association with race, ethnicity, and socioeconomic factors.

Authors:  Dana Albon; Aricca D Van Citters; Thida Ong; Olivia Dieni; Christopher Dowd; Anne Willis; Kathryn A Sabadosa; Peter Scalia; Kimberly Reno; Gabriela R Oates; Michael S Schechter
Journal:  J Cyst Fibros       Date:  2021-12       Impact factor: 5.482

8.  Cystic fibrosis in South Africa: spectrum of disease and determinants of outcome.

Authors:  Marco Zampoli; Janine Verstraete; Marlize Frauendorf; Reshma Kassanjee; Lesley Workman; Brenda M Morrow; Heather J Zar
Journal:  ERJ Open Res       Date:  2021-08-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.